アジア太平洋地域の移植片対宿主病（GVHD）治療市場規模、シェア、トレンド分析レポート
Market Size in USD Billion
CAGR :
% 
USD
478.64 Million
USD
638.70 Million
2024
2032
 予測期間 |
2025 –2032 |
 市場規模（基準年） |
USD 478.64 Million |
 Market Size (Forecast Year) |
USD 638.70 Million |
 CAGR |
% |
| Major Markets Players |
|
アジア太平洋地域の移植片対宿主病（GVHD）治療市場：治療（薬物療法および療法）、タイプ（慢性GVHD、急性GVHD、予防）、性別（女性および男性）、年齢（成人および小児）、投与方法（経口、静脈内、局所、およびその他）、エンドユーザー（病院、移植センター、研究所、および専門センター）、流通チャネル（直接入札、小売販売、およびその他）別 - 2032年までの業界動向および予測
アジア太平洋地域の移植片対宿主病（GVHD）治療市場規模
- アジア太平洋地域の移植片対宿主病（GVHD）治療市場は2024年に4億7,864万米ドルと評価され、 2032年までに6億3,870万米ドルに達すると予想されています。
- 2025年から2032年の予測期間中、市場は主に肥満の蔓延の増加に牽引され、4.2%のCAGRで成長すると予想されます。
- この成長は、移植片対宿主病（GVHD）治療薬のイノベーション、肥満外科手術および代謝外科手術の拡大といった要因によって牽引されています。さらに、移植片対宿主病（GVHD）治療におけるデジタルヘルスソリューションの統合もその要因の一つです。
アジア太平洋地域の移植片対宿主病（GVHD）治療市場分析
- 幹細胞移植の増加と治療法の進歩は、市場の成長を牽引する主な要因の一部です。
- さらに、新しい治療法の開発が市場の成長をさらに促進しています。しかし、市場の成長を阻害する大きな要因は、治療に伴う高額な費用です。
- 一方、医療従事者、患者、介護者の間でGVHDに関する意識と教育が高まることで、市場の成長機会が創出されると期待されます。しかしながら、感染症やその他の合併症のリスクは、市場の成長にとって課題となることが予想されます。
- 北米は、確立された医療インフラ、高い罹患率、そして体重管理ソリューションの継続的な研究に支えられ、アジア太平洋の移植片対宿主病（GVHD）治療市場において依然として主要な地域です。
- 移植片対宿主病（GVHD）の管理と予防医療への重点が高まる中、アジア太平洋市場では、新しい治療法、医療技術、患者中心のソリューションへの多額の投資が行われており、業界全体の拡大を牽引しています。
レポートの範囲と移植片対宿主病（GVHD）治療市場のセグメンテーション
|
属性 |
アジア太平洋地域の移植片対宿主病（GVHD）治療市場における主要な市場洞察 |
|
対象セグメント |
|
|
対象国 |
アジア太平洋
|
|
主要な市場プレーヤー |
|
|
市場機会 |
|
|
付加価値データ情報セット |
データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、輸出入分析、生産能力概要、生産消費分析、価格動向分析、気候変動シナリオ、サプライチェーン分析、バリューチェーン分析、原材料/消耗品概要、ベンダー選択基準、PESTLE分析、ポーター分析、規制枠組みも含まれています。 |
アジア太平洋地域の移植片対宿主病 (GVHD) 治療市場の動向。
「造血幹細胞移植（HSCT）の発生率の増加」
- この傾向は、白血病、リンパ腫、骨髄腫といった血液がんの増加が主な要因であり、これらの疾患はしばしば治療選択肢として造血幹細胞移植（HSCT）を必要とします。さらに、再生不良性貧血や特定の遺伝性疾患といった他の血液疾患も、疾患管理のために造血幹細胞移植を必要とします。
- 造血幹細胞移植（HSCT）を受ける患者数の増加に伴い、効果的なGVHD治療への需要も高まっています。GVHDはHSCTの一般的な合併症であり、移植されたドナー細胞がレシピエントの組織を攻撃することで発生し、重篤で生命を脅かす可能性のある症状を引き起こします。したがって、HSCTの罹患率の増加は、この合併症の影響を管理・軽減するためのGVHD治療の必要性の高まりに直接つながります。
例えば、
- 2023年10月、Frontiers Media SAが発表した記事によると、移植件数は世界中で着実に増加しており、2019年には欧州血液骨髄移植学会（EBMT）が約2万件の同種造血幹細胞移植を報告し、国際血液骨髄移植研究センター（CIBMTR）によると、同時期に米国では9,000件以上の移植が行われた。
世界の移植片対宿主病（GVHD）治療市場の動向
ドライバ
「啓発キャンペーンと患者教育の向上」
- 啓発キャンペーンと患者教育は、移植片対宿主病（GVHD）の早期発見と治療において極めて重要です。医療従事者、患者、そして介護者を特に対象としたこれらの取り組みは、GVHDの主要な症状を浮き彫りにし、迅速な認識と適切な介入を可能にします。
- 十分な知識を持つ患者と介護者は、早期に医師の診察を受ける可能性が高く、病気が重症化するのを予防できます。さらに、GVHDの兆候と管理に精通した医療従事者は、より効果的なケアを提供し、患者の転帰を改善することができます。こうした的を絞った取り組みは、GVHDに苦しむ人々の生活の質（QOL）全体を向上させる上で非常に重要です。
例えば、
- 2023年8月、Fierce Pharmaの記事によると、サッカー界のレジェンド、ミア・ハム選手がIncyte社と提携し、移植片対宿主病（GVHD）への意識向上に取り組んでいます。ハム選手は、1997年に骨髄移植（BMT）後の合併症で兄のギャレットさんを亡くした自身の経験を語ります。希少な骨髄疾患の治療を目的としたBMTは、移植片の免疫細胞がレシピエントの細胞を攻撃するGVHDの大きなリスクを伴います。この病態は移植後に管理が困難になる場合があり、場合によっては致命的となることもあります。
- 2023年2月、PR Newswireは、米国で主要な移植組織で構成されるGVHDアライアンスが新たに結成され、移植片対宿主病（GVHD）に苦しむ人々へのリソースとサポートへのアクセス向上を目指していると報じました。このアライアンスは、GVHDコミュニティへの意識向上と支援を高めるため、2月17日をGVHDデーと定めました。加盟組織には、米国移植・細胞療法学会（ASTCT）、Be The Match（全米骨髄ドナープログラム運営）、血液・骨髄移植情報ネットワーク（BMT InfoNet）、メレディス・A・カウデン財団、全米骨髄移植リンク（nbmtLINK）などがあります。このアライアンスは、患者をソーシャルワーカーや患者ナビゲーターなどの支援グループやリソースと結び付け、治療への支持や懸念事項への対処を支援することを目指しています。
機会
「戦略的イニシアチブとパートナーシップによる市場拡大」
- 戦略的提携による市場拡大は、GVHD（移植片対宿主病）治療市場で事業を展開する企業にとって非常に効果的なアプローチとなり得る。
- GVHDに対する革新的な治療法と包括的なケアソリューションの需要が高まる中、企業は戦略的パートナーシップや協業を活用して市場プレゼンスを拡大し、変化する患者ニーズに合わせた多様な製品ポートフォリオを提供することができます。研究機関、学術機関、バイオテクノロジー企業と連携することで、GVHD市場のプレーヤーは最先端技術、革新的な治療法、科学的専門知識を活用し、製品開発を推進することができます。
- これらの連携により、企業は個別化細胞療法、標的生物学的製剤、支持療法介入など、有望なGVHD治療法の発見と開発を加速することができます。
- さらに、主要なオピニオンリーダーや患者擁護団体との戦略的提携により、信頼、信用、患者の関与を促進し、市場へのアクセスを容易にし、新しい治療法の採用を促進します。
- 2021年3月、ブリストル・マイヤーズ スクイブ社が発表した記事によると、ブリストル・マイヤーズ スクイブ社（BMS）とブルーバード・バイオ社は戦略的提携を結び、アベクマ社を共同開発しました。アベクマ社は、トリプルクラスの抗がん剤を投与された多発性骨髄腫患者に単回投与される、画期的なBCMA標的個別化免疫細胞療法です。アベクマ社は、移植片対宿主病（GVHD）の治療に特化して設計された、B細胞成熟抗原（BCMA）抗原受容体T細胞療法です。この提携は、ブルーバード・バイオ社の細胞療法に関する深い専門知識と、BMS社の広範なグローバルな商業化能力を活用しています。その目標は、革新的な治療選択肢を発展させることで、将来的にGVHD患者の満たされていない医療ニーズに対応し、GVHD分野における画期的な治療法への道を開くことです。
- 2022年11月、Labiotech UGの調査によると、ノバルティスはガミダ・セル社と提携し、高リスクの造血悪性腫瘍患者を対象とした治験段階の先進的細胞療法であるオミデュビセルの開発・商業化に着手しました。オミデュビセルは、移植用幹細胞の利用可能性を高めることで、骨髄移植の転帰を向上させることを目指しています。この提携は、GVHD治療への応用も視野に入れ、造血腫瘍学分野における未充足ニーズへの対応を目指す戦略的取り組みです。
- さらに、戦略的イニシアチブによる市場拡大により、GVHD市場のプレーヤーは製品ポートフォリオを多様化し、GVHD市場のより大きなシェアを獲得することができます。
抑制/挑戦
「GVHD治療における厳格な規制」
- GVHDに関する規制ガイドラインは、従来のものに比べて厳格化されています。製造業者は承認前に具体的な製品変更を行う必要があり、遅延が生じることが予想されます。
- 厳格な規制は、GVHD市場にとって将来的に大きな課題となるでしょう。この分野は新たな治療法や治療モダリティの開発によって進歩を続けており、規制当局は安全性、有効性、品質管理に関して厳格な基準を課しています。
- これらの規制要件を満たすには、前臨床および臨床開発への多大な投資、そして規制承認のための広範な文書作成とデータ提出が必要です。さらに、GVHDの複雑性、その多様な症状、そして標準化された診断基準の欠如は、規制当局による評価および承認プロセスをさらに複雑化させます。
- 例えば、
- FDAが発表した記事によると、2023年4月には米国で幹細胞研究が合法化されました。しかし、その資金提供には一定の制限があります。米国生物学的製剤評価研究センター（CBER）は、細胞治療製品、ヒト遺伝子治療製品、および細胞・遺伝子治療に関連する特定の機器を規制しています。FDAは治療法の安全性と有効性を確保する上で重要な役割を果たしていますが、規制プロセスは厳格で時間がかかる場合があります。さらに、FDAの規制環境は変化し続けており、市販後調査の要件も厳格であるため、継続的なコンプライアンスへの取り組みが必要となり、新しい治療法が市場に投入される速度に影響を与える可能性があります。
- 厳しい規制は、将来的にGVHD市場にとって大きな課題となり、製品開発のタイムライン、コスト、市場アクセスに影響を与える。
アジア太平洋地域の移植片対宿主病（GVHD）治療市場の展望
市場は、タイプ、製品タイプ、吸収部位、年齢層、供給源、配送方法、性別、流通チャネルに基づいてセグメント化されています。
|
セグメンテーション |
サブセグメンテーション |
|
|
|
|
。 |
|
|
|
|
|
|
|
|
|
アジア太平洋地域の移植片対宿主病（GVHD）治療市場の地域分析
「日本は移植片対宿主病（GVHD）治療市場において主要な地域です」
- 日本は、肥満率の高さ、高度な医療インフラ、革新的な体重管理ソリューションの積極的な導入により、アジア太平洋地域の移植片対宿主病（GVHD）治療市場をリードしています。
- 日本は、GLP-1受容体作動薬、肥満手術、デジタル体重管理プラットフォームなどの薬物治療の需要の高まりにより、大きな市場シェアを占めています。
- さらに、健康リスクに関する意識の高まりと、AIを活用した減量プログラム、遠隔医療相談、非侵襲的治療ソリューションの導入の増加が、この地域の市場拡大を促し続けています。
「日本は最も高い成長率を記録すると予測されている」
- 日本地域は、移植片対宿主病（GVHD）の罹患率の増加、医療投資の増加、体重管理ソリューションに対する意識の高まりにより、アジア太平洋の移植片対宿主病（GVHD）治療市場において最も高い成長率を示すことが予想されています。
- 日本のような国は、ライフスタイルの変化、都市化の進展、肥満に関連する健康上の合併症の増加により、重要な市場として浮上している。
- 日本は、医療インフラの拡大と医療による減量治療の需要増加により、移植片対宿主病（GVHD）管理において依然として重要な市場です。薬物療法、肥満手術、デジタル体重管理プログラムの導入が進んでいます。
市場競争環境は、競合他社ごとに詳細な情報を提供します。企業概要、財務状況、収益、市場ポテンシャル、研究開発投資、新規市場への取り組み、アジア太平洋地域におけるプレゼンス、生産拠点・設備、生産能力、強みと弱み、製品投入、製品群の幅広さ、アプリケーションにおける優位性などの詳細が含まれます。上記のデータは、各社の市場への注力分野にのみ関連しています。
市場で活動している主要なマーケットリーダーは次のとおりです。
- ブリストル・マイヤーズ スクイブ社（米国）
- アッヴィ社（米国）
- ノバルティスAG（スイス）
- ヤンセン・グローバル・サービスLLC（米国）
- マリンクロット（米国）
- インサイト（米国）
- サノフィ（フランス）
- アルケムラボラトリーズ株式会社（インド）
- アステラス製薬株式会社（日本）
アジア太平洋地域の移植片対宿主病（GVHD）治療市場の最新動向
- 2025年2月、米国FDAは、治療選択肢が限られている成人の複雑性腹腔内感染症（cIAI）の治療薬として、モノバクタム系抗生物質とβ-ラクタマーゼ阻害剤の併用療法として初のEMBLAVEO（アズトレオナムとアビバクタム）を承認しました。本剤は、耐性株を含むグラム陰性菌を標的としています。この承認は、アジア太平洋地域における重大な健康上の脅威である抗菌薬耐性の増加に対処するものです。
- 2024年2月、ジョンソン・エンド・ジョンソンは、パートナーであるPharmacyclics LLC（アッヴィ傘下）と共に、経口懸濁液剤であるIMBRUVICA（イブルチニブ）の適応拡大についてFDAの承認を取得しました。この適応拡大により、全身療法後の慢性リンパ性白血病（CLL/SLL）、白血病（WM）、およびcGVHDの成人患者への治療が可能になります。
- 2024年3月、ジョンソン・エンド・ジョンソンは、アンブレックス・バイオファーマ社の買収を完了したことを発表しました。臨床段階にあるこのバイオ医薬品企業は、次世代の抗体薬物複合体（ADC）の設計・開発に使用される独自の合成生物学技術プラットフォームを保有しています。この買収により、ジョンソン・エンド・ジョンソンは標的型がん治療薬の創出、開発、販売というユニークな機会を得ることになります。
- 2024年2月、アッヴィ社とテンタリックス・バイオセラピューティクス社は、腫瘍学および免疫学の分野における条件付き活性型多剤耐性生物製剤の共同研究・開発に関する提携を発表しました。この提携では、アッヴィ社のこれらの分野における豊富な経験と、テンタリックス社独自のTentaclesプラットフォームを活用します。
- サノフィは2021年9月、アンメットメディカルニーズの高い疾患に対する革新的な治療法の開発と商業化に注力するバイオ医薬品企業であるカドモン・ホールディングス社との合併契約を締結しました。この買収は、サノフィのジェネラルメディシンズ事業における中核資産の成長戦略に合致しており、レズロック（ベルモスジル）を速やかに移植ポートフォリオに組み込むことになります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT)
6.1.2 RISING AWARENESS CAMPAIGNS AND PATIENT EDUCATION
6.1.3 ADVANCEMENTS IN TREATMENT OPTIONS FOR GRAFT-VERSUS-HOST DISEASE (GVHD)
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE
6.2.2 DISEASE HETEROGENEITY IN GRAFT-VERSUS-HOST DISEASE (GVHD) IMPLICATIONS FOR TREATMENT AND CLINICAL TRIALS
6.3 OPPORTUNITIES
6.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP
6.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT
6.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES
6.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT
7 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY TYPE
7.1 OVERVIEW
7.2 CHRONIC GVHD
7.2.1 CORTICOSTEROIDS
7.2.1.1 PREDNISOLONE
7.2.1.2 METHYLPREDNISOLONE
7.2.2 IMMUNOSUPPRESSIVE
7.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.2.2.2 METHOTREXATE (MTX)
7.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
7.2.2.4 OTHERS
7.2.3 CALCINEURIN INHIBITORS
7.2.4 OTHERS
7.2.5 BRANDED
7.2.5.1 REZUROCK
7.2.5.2 IMBRUVICA
7.2.5.3 JAKAFI
7.2.6 GENERIC
7.3 ACUTE GVHD
7.3.1 CORTICOSTEROIDS
7.3.1.1 METHYLPREDNISOLONE
7.3.1.2 PREDNISOLONE
7.3.2 IMMUNOSUPPRESSIVE
7.3.2.1 MYCOPHENOLATE MOFETIL (MMF)
7.3.2.2 RUXOLITINIB
7.3.2.3 OTHERS
7.3.3 CALCINEURIN INHIBITORS
7.3.3.1 TACROLIMUS (TAC)
7.3.3.2 CYCLOSPORIN (CSA)
7.3.4 OTHERS
7.4 PROPHYLACTIC
7.4.1 CYCLOSPORIN (CSA)
7.4.2 METHOTREXATE (MTX)
7.4.3 TACROLIMUS (TAC)
7.4.4 METHYLPREDNISOLONE
7.4.5 OTHERS
7.4.6 GENERIC
7.4.7 BRANDED
8 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY AGE
8.1 OVERVIEW
8.2 ADULTS
8.3 PEDIATRIC
9 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER
9.1 OVERVIEW
9.2 FEMALE
9.3 MALE
10 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION
10.1 OVERVIEW
10.2 ORAL
10.3 INTRAVENOUS
10.4 TOPICAL
10.5 OTHERS
11 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 CORTICOSTEROIDS
11.2.1.1 METHYLPREDNISOLONE
11.2.1.2 PREDNISOLONE
11.2.2 IMMUNOSUPPRESSIVE
11.2.2.1 MYCOPHENOLATE MOFETIL (MMF)
11.2.2.2 METHOTREXATE (MTX)
11.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG)
11.2.2.4 OTHERS
11.2.3 CALCINEURIN INHIBITORS
11.2.3.1 TACROLIMUS (TAC)
11.2.3.2 CYCLOSPORIN (CSA)
11.2.3.3 OTHERS
11.2.4 BRANDED
11.2.4.1 REZUROCK
11.2.4.2 IMBRUVICA
11.2.4.3 JAKAFI
11.2.4.4 ORENCIA
11.2.4.5 OTHERS
11.2.5 GENERIC
11.3 THERAPY
12 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PUBLIC
12.2.2 PRIVATE
12.3 TRANSPLANT CENTERS
12.4 INSTITUTES
12.5 SPECIALITY CENTERS
13 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION
14.1 ASIA-PACIFIC
14.1.1 JAPAN
14.1.2 CHINA
14.1.3 AUSTRALIA
14.1.4 SOUTH KOREA
14.1.5 INDIA
14.1.6 MALAYSIA
14.1.7 SINGAPORE
14.1.8 PHILIPPINES
14.1.9 INDONESIA
14.1.10 REST OF ASIA-PACIFIC
15 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 BRISTOL-MYERS SQUIBB COMPANY
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 ABBVIE INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 JANSSEN ASIA-PACIFIC SERVICES, LLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 SANOFI
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS/NEWS
17.5 INCYTE
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ALKEM LABORATORIES LTD.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 ASTELLAS PHARMA INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 MALLINCKRODT
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS/NEWS
17.9 NOVARTIS AG
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
表のリスト
TABLE 1 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 10 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 12 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC ADULTS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC PEDIATRIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC FEMALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 20218-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC MALE IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 23 ASIA-PACIFIC ORAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC INTRAVENOUS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC TOPICAL IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC OTHERS IN GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC THERAPY IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC TRANSPLANT CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC INSTITUTES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC SPECIALTY CENTERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC DIRECT TENDER IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC OTHERS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 74 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 75 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 76 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 77 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 78 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 79 JAPAN MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 83 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 84 JAPAN IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 85 JAPAN CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 JAPAN BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 JAPAN ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 88 JAPAN CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 89 JAPAN IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 90 JAPAN CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 91 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 92 JAPAN PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 94 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 95 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 96 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 97 JAPAN HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 98 JAPAN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 99 JAPAN RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 100 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 101 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 102 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 103 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 104 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 105 CHINA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 109 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 110 CHINA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 111 CHINA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 CHINA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 CHINA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 114 CHINA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 115 CHINA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 116 CHINA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 117 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 118 CHINA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 120 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 121 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 122 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 123 CHINA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 124 CHINA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 125 CHINA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 126 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 127 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 128 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 129 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 130 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 131 AUSTRALIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 135 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 136 AUSTRALIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 137 AUSTRALIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 AUSTRALIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 AUSTRALIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 140 AUSTRALIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 141 AUSTRALIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 142 AUSTRALIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 143 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 144 AUSTRALIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 146 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 147 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 148 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 149 AUSTRALIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 150 AUSTRALIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 151 AUSTRALIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 152 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 153 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 154 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 155 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 156 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 157 SOUTH KOREA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 161 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 162 SOUTH KOREA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 163 SOUTH KOREA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 SOUTH KOREA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 SOUTH KOREA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 166 SOUTH KOREA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 167 SOUTH KOREA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 168 SOUTH KOREA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 169 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 170 SOUTH KOREA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 172 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 173 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 174 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 175 SOUTH KOREA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 176 SOUTH KOREA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 177 SOUTH KOREA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 178 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 179 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 180 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 181 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 182 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 183 INDIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 187 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 188 INDIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 189 INDIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 INDIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 INDIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 192 INDIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 193 INDIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 194 INDIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 195 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 196 INDIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 198 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 199 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 200 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 201 INDIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 202 INDIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 203 INDIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 204 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 205 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 206 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 207 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 208 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 209 MALAYSIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 213 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 214 MALAYSIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 215 MALAYSIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 MALAYSIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 MALAYSIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 218 MALAYSIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 219 MALAYSIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 220 MALAYSIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 221 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 222 MALAYSIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 224 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 225 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 226 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 227 MALAYSIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 228 MALAYSIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 229 MALAYSIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 230 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 231 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 232 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 233 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 234 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 235 SINGAPORE MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 239 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 240 SINGAPORE IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 241 SINGAPORE CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 SINGAPORE BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 SINGAPORE ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 244 SINGAPORE CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 245 SINGAPORE IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 246 SINGAPORE CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 247 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 248 SINGAPORE PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 249 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 250 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 251 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 252 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 253 SINGAPORE HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 254 SINGAPORE GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 255 SINGAPORE RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 256 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 257 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 258 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 259 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 260 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 261 PHILIPPINES MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 264 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 265 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 266 PHILIPPINES IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 267 PHILIPPINES CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 PHILIPPINES BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 PHILIPPINES ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 270 PHILIPPINES CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 271 PHILIPPINES IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 272 PHILIPPINES CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 273 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 274 PHILIPPINES PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 276 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 277 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 278 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 279 PHILIPPINES HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 280 PHILIPPINES GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 281 PHILIPPINES RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 282 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 283 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 284 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 285 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 286 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 287 INDONESIA MEDICATION IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 291 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 292 INDONESIA IMMUNOSUPPRESSIVE IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 293 INDONESIA CHRONIC GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 INDONESIA BRANDED IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 295 INDONESIA ACUTE GVHD IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 296 INDONESIA CORTICOSTEROIDS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 297 INDONESIA IMMUNOSUPPRESSIVES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 298 INDONESIA CALCINEURIN INHIBITORS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 299 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUGS, 2018-2032 (USD THOUSAND)
TABLE 300 INDONESIA PROPHYLACTIC IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 302 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY AGE, 2018-2032 (USD THOUSAND)
TABLE 303 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 304 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 305 INDONESIA HOSPITALS IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 306 INDONESIA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 307 INDONESIA RETAIL SALES IN GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 308 REST OF ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
図表一覧
FIGURE 1 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SEGMENTATION
FIGURE 11 THE GROWING NUMBER OF STEM CELL TRANSPLANTATIONS IS DRIVING THE GROWTH OF THE ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET IN 2025 AND 2032
FIGURE 13 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET
FIGURE 17 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2024
FIGURE 18 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 20 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2024
FIGURE 22 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, 2025-2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, CAGR (2025-2032)
FIGURE 24 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2024
FIGURE 26 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2024
FIGURE 30 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY METHOD OF ADMINISTRATION, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 34 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER 2024
FIGURE 38 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 39 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, CAGR (2025-2032)
FIGURE 40 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: END USER, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 42 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 43 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 44 ASIA-PACIFIC GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET: DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 ASIA-PACIFIC GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 46 ASIA-PACIFIC GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY SHARE 2024 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
